Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Alla Lisyanskaya
Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive, Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial
The Lancet Oncology
Oncology
Related publications
Olaparib Combined With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
The Lancet Oncology
Oncology
ENGOT-ov-6/TRINOVA-2: Randomised, Double-Blind, Phase 3 Study of Pegylated Liposomal Doxorubicin Plus Trebananib or Placebo in Women With Recurrent Partially Platinum-Sensitive or Resistant Ovarian Cancer
European Journal of Cancer
Cancer Research
Oncology
CONFIRM: A Double-Blind, Placebo-Controlled Phase III Clinical Trial Investigating the Effect of Nivolumab in Patients With Relapsed Mesothelioma: Study Protocol for a Randomised Controlled Trial
Trials
Medicine
Pharmacology
Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial
The Lancet
Medicine
Etanercept in Alzheimer Disease: A Randomized, Placebo-Controlled, Double-Blind, Phase 2 Trial
Neurology
Neurology
Photodynamic Therapy for Dysplastic Barrett's Oesophagus: A Prospective, Double Blind, Randomised, Placebo Controlled Trial
Gut
Gastroenterology
A Randomised, Double-Blind, Placebo-Controlled Multi-Centre Phase III Trial of XELIRI/FOLFIRI Plus Simvastatin for Patients With Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
Bumetanide in Hypokalaemic Periodic Paralysis: A Randomised, Double-Blind, Placebo Controlled Phase II Clinical Trial With a Crossover Design
Neuromuscular Disorders
Child Health
Neurology
Pediatrics
Perinatology
Genetics
Docetaxel and Dasatinib or Placebo in Men With Metastatic Castration-Resistant Prostate Cancer (READY): A Randomised, Double-Blind Phase 3 Trial
The Lancet Oncology
Oncology
